Document text
Principal Investigator: Mariah L Arral
Organization: CARNEGIE-MELLON UNIVERSITY
Fiscal Year: 2024
Award: $45,094
Funding agency: National Institute on Aging
PROJECT ABSTRACT
The goal of this research is to study the influence of age on the delivery processes required for lipid
nanoparticle-mediated mRNA vaccination, with a long-term goal of improving vaccination outcomes in the
elderly. In the next thirty years, our elderly population will double, exceeding 1.6 billion people worldwide.
Unfortunately, a declining immune system makes elderly people susceptible to an array of deadly infectious
diseases, placing additional burdens on global healthcare, particularly during epidemics and pandemics such
as Ebola and SARS-CoV-2. There is a real need for effective prophylactics that protect vulnerable populations.
Messenger RNA (mRNA) has emerged as a revolutionary platform that has catalyzed the fastest development
of vaccines in history and bolstered the fight against SARS-CoV-2. However, early data suggest that these
vaccines elicit an age-dependent immune response. The diminished antibody response of these vaccines in
the elderly can substantially curtail their duration of protection. There is an urgent need to understand mRNA
delivery as a function of age and develop potent and safe vaccines that can protect people across all age
groups. While other researchers are examining age-related immune system impairment, this research is
unique because it will determine age-related effects on the lipid nanoparticle (LNP) mRNA delivery
process. This will enable the decoupling of impaired delivery and diminished immune responses on mRNA
vaccination in the elderly. I am well-poised to conduct this research, given my preliminary data and the
expertise of the Whitehead and Weissman labs with LNP delivery, immunology, and vaccinology.
Although measuring post-vaccination infection rates and antibody titers as a function of age is
important, these endpoints do not capture the effect of age on critical intermediate steps during mRNA
vaccination. I hypothesize that differences in delivery contribute to reductions in mRNA-induced immunity. To
test this hypothesis, I will determine to what extent age affects lipid nanoparticle mRNA delivery endpoints (Aim
1) and immune responses (Aim 2), allowing the two to be decoupled. In Aim 1, I will determine the efficacy,
biodistribution, targeted cell population, immunogenicity, and toxicity of five top-performing lipid nanoparticles
following intramuscular injection in young and old mice of both sexes. In Aim 2, I will elucidate the impact of
age on the immune response of mRNA-LNPs. From Aim 2.1, we will select a top-performing LNP to investigate
further in a vaccine kinetics study (Aim 2.2). Aims 1 and 2 combined will reveal LNP structures that confer the
most robust immune response in young and old mice and aid the development of more efficacious mRNA
vaccines for the elderly.
This work is innovative because we will study how age impacts the process of nanoparticle delivery, which has
not been conducted comprehensively for mRNA-LNPs. In the long term, our discoveries will have clinical
significance because they will help tailor the design of LNP delivery systems for the elderly.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><65 and older><65 or older><65 years of age and older><65 years of age or more><65 years of age or older><65+ years><65+ years old><> 65 years><Affect><Age><Aged 65 and Over><Aging><Antibody Response><Antibody titer measurement><Assay><Bioassay><Biodistribution><Biological><Biological Assay><Body Tissues><COVID-19 virus><COVID19 virus><Cell Body><Cells><Circulation><Clinical><CoV-2><CoV2><Communicable Diseases><Data><Development><Dose><Drugs><ELISA><Ebola><Elderly><Enzyme-Linked Immunosorbent Assay><Epidemic><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Foreign Bodies><Formulation><Goals><Healthcare><History><Immune><Immune Cell Activation><Immune response><Immune system><Immunes><Immunity><Immunochemical Immunologic><Immunologic><Immunological><Immunological response><Immunologically><Immunologics><Immunology><Impairment><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Intramuscular><Intramuscular Injections><Investigators><Kinetics><Measures><Mediating><Medication><Memory><Memory B Cell><Memory B-Lymphocyte><Messenger RNA><Methods><Mice><Mice Mammals><Modeling><Murine><Mus><Outcome><Ovalbumin><Patients><Performance><Persons><Pharmaceutical Preparations><Physiologic><Physiological><Population><Position><Positioning Attribute><Predisposition><Process><Proteins><RNA immunization><RNA vaccination><RNA vaccine><RNA-based vaccine><Recording of previous events><Reporter><Research><Research Personnel><Researchers><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Serology><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Structure><Subgroup><Susceptibility><System><T-Cells><T-Lymphocyte><Testing><Therapeutic><Time><Tissues><Toxic effect><Toxicities><Toxicology><Transfection><Vaccination><Vaccine Production><Vaccines><Variant><Variation><Vulnerable Populations><Work><Wuhan coronavirus><above age 65><adult youth><advanced age><after age 65><age 65 and greater><age 65 and older><age 65 or older><age > 65><age associated><age associated alterations><age associated changes><age associated difference><age associated effects><age based difference><age correlated><age correlated alterations><age correlated changes><age dependent><age dependent alterations><age dependent changes><age dependent difference><age dependent variation><age difference><age effect><age group><age linked><age of 65 years onward><age related><age related alterations><age related changes><age related difference><age related effects><age related variation><age specific><age specific alterations><age specific changes><age specific difference><aged 65 and greater><aged 65+><aged mice><aged mouse><aged ≥65><ages><aging effect><alterations with age><antibody titering><biologic><changes with age><clinical significance><clinically significant><coronavirus disease 2019 virus><coronavirus disease-19 virus><cytokine><deliver mRNA><deliver messenger RNA><delivery system for mRNA><design><designing><determine efficacy><develop a vaccine><develop vaccines><development of a vaccine><developmental><differ by age><difference across age><difference in age><dosage><drug/agent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><elderly mice><enzyme linked immunoassay><evaluate efficacy><examine efficacy><experience><fighting><flow cytophotometry><geriatric><global health><hCoV19><health care><histories><host response><human old age (65+)><imaging in vivo><immune activation><immune response to vaccination><immune response to vaccines><immune senescence><immune system response><immunogenic><immunogenicity><immunoresponse><immunosenescence><impact of age><improved><in vivo imaging><infection rate><influence of age><innovate><innovation><innovative><intramuscular drug administration><lipid based nanoparticle><lipid nanoparticle><mRNA><mRNA delivery><mRNA immunization><mRNA vaccination><mRNA vaccine><mRNA-based vaccine><messenger RNA delivery><nCoV2><nano particle><nano particle delivery><nano process><nano-sized particle><nanoparticle><nanoparticle delivered><nanoparticle delivery><nanoprocess><nanosized particle><next generation><old age><old mice><outcome following vaccination><outcome following vaccine><over 65 years><pandemic><pandemic disease><produce vaccines><prophylactic><rate of infection><response><result following vaccination><result following vaccine><senior citizen><sex><thymus derived lymphocyte><uptake><vaccination outcome><vaccination result><vaccine associated immune response><vaccine development><vaccine efficacy><vaccine immune response><vaccine immunogenicity><vaccine induced immune response><vaccine outcome><vaccine response><vaccine responsiveness><vaccine result><vaccine-induced response><vaccinology><variation by age><vulnerable group><vulnerable individual><vulnerable people><young adult><young adulthood><≥65 years>